Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

11 Feb 2021

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

TORONTO, Feb....

By Microdose

Press Releases

11 Feb 2021

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

SwitzerlandFeb....

By Microdose

Press Releases

11 Feb 2021

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

La Jolla, California–(Newsfile Corp....

By Microdose

Press Releases

10 Feb 2021

REPEAT – Pure Extracts Announces Its First Commercial Sale of CBD Oil on the Wholesale Market

VANCOUVER, British Columbia, Feb....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

10 Feb 2021

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

10 Feb 2021

NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

10 Feb 2021

Pure Extracts Announces Its First Commercial Sale of CBD Oil on the Wholesale Market

VANCOUVER, British Columbia, Feb....

By Microdose

Press Releases

9 Feb 2021

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

TORONTO, Feb....

By Microdose

Press Releases

9 Feb 2021

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica

TORONTO, Feb....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.